SEATTLE, WA--(Marketwired - September 24, 2013) -
Atossa Genetics, Inc. (NASDAQ: ATOS
), The Breast Health Company™, announced today that Kyle Guse, Chief Financial Officer & General Counsel, will present the Company's products, services and business strategy at the 2013 Aegis Capital Healthcare Conference on Friday, September 27, 2013, beginning at 9:45 am Pacific Time. The conference will be held at the Encore at Wynn Las Vegas, 3131 Las Vegas Boulevard South, Las Vegas, Nevada.
Management will be available for one-on-one meetings with the investment community during the conference. Please contact Aegis conference organizers if you would like to arrange a meeting.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests. The lead test is called the ForeCYTE Breast Health Test, which can detect precursors to breast cancer up to eight years before mammography.
The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information, on Atossa and the NRLBH, please visit www.atossagenetics.com and www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit www.getforecyte.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.